你好, 我们平台 token8341(token8341.com)提供 AI 大模型 API 聚合服务, 一个 key 调用 DeepSeek、Kimi、智谱 GLM、通义千问、MiniMax 等模型, 完全兼容 OpenAI SDK。 想跟你聊聊是否有合作可能。回这封邮件就能找到我。谢谢! --- 吴琼 token8341 https://www.token8341.com -- 不想再收到我们的邮件?直接回复本邮件、正文写「退订」两个字即可(或点击「回复」后发送空邮件),我们会在 24 小时内把你移出名单,之后不再发送任何营销邮件。
Thursday, October 29, 2026
Saturday, July 4, 2026
Fwd: Quantum for Life Sciences
for a title, how about : " Applications of Quantum Computing in Biomedical Data Science " For a short abstract, how about : " My talk will cover various applications of quantum computing (QC) in biomedical data science. In particular, I will discuss : (1) How can we use QC for ML in defined biomedical problems. (2) The use of quantum representations for achieving biomedical privacy. (3) Fitting QC into larger biomedical workflows. The talk will include material from the following papers: https://arxiv.org/abs/2509.12465 https://journals.aps.org/pra/abstract/10.1103/PhysRevA.111.042416 https://academic.oup.com/bioinformatics/article/39/1/btac789/6881079 https://www.nature.com/articles/s41592-020-01004-3 " == i0ismb26
Wednesday, July 1, 2026
Abstract for Oxford talk (eur26+ox)
TITLE: AI in Structural Bioinformatics: ABSTRACT : This talk covers AI methods in structural bioinformatics, with a focus on modeling protein flexibility and disorder. It introduces DreamFold, an AI "world model" that learns folding pathways in latent space, replacing a slower classical sampling approach (discard-and-restart). It presents machine-learning improvements to Kohn-Sham Hamiltonian estimation for faster DFT calculations on larger molecules. It also shows that ensembles of sequence-based deep learning models outperform individual predictors and 3D docking for drug screening. Finally, it addresses protein aggregation in disease (e.g., AD) via liquid-liquid phase separation (LLPS), using LLM embeddings and graph neural networks to predict LLPS-prone regions, intrinsically disordered regions (IDRs), and the effects of specific mutations.
Monday, June 29, 2026
Fwd: Mark Gerstein's talk at the CRG (July 21st 2026)
TITLE: Topics in Neurogenomics: Using AI to Study Endophenotypes & then Having it Take Over ABSTRACT: This talk explores the use of AI to study and eventually drive neurogenomics research. It covers linking wearable-derived "digital phenotypes" to genotype for conditions like ADHD, showing this approach uncovers SNPs missed by traditional case-control GWAS. It then examines single-cell data (e.g., PsychENCODE's 388-brain dataset) to build cell-type-specific regulatory and cell-to-cell communication networks, integrating them into deep learning models that predict disease from genotype and suggest drug targets. Finally, it turns to having AI do the science itself — automatically generating bioinformatics code, coordinating multi-agent LLM systems for unified reasoning, and considering the future risks of AI scientists in biomedicine. eur26+CRG
Abstract for my talk at UB (eur26+UB)
TITLE: The Changing Challenges in Human Genome Analysis ABSTRACT: This talk covers four areas: the EN-TEx resource for haplotype-aware genome analysis, classical genome annotation (pseudogene epigenetics across tissues), linking genetic variants to function via an allele-specific event catalog and a predictive transformer model, and new challenges in genomics -- privacy-preserving methods for handling population-scale disease genome data (homomorphic encryption, private federated learning, and leakage measurement). REFS: https://papers.gersteinlab.org/papers/NoisyFlow https://papers.gersteinlab.org/papers/HEPRS https://papers.gersteinlab.org/papers/epiPgene https://papers.gersteinlab.org/papers/Entex
Friday, April 10, 2026
Business Meeting Request 1191946
Dear Sir/Ma - I an Ericka, a Financial Consultant in Oman. I work with different private investors that can invest in your projects and ongoing project or a stratup. If you are intrested, i would provide you with more information. Looking forward to speaking with you Best Regards Ericka
Tuesday, March 3, 2026
[ glabstracts.mbglab ] Quota 99.82%
| Mailbox quota notification for "glabstracts.mbglab@blogger.com". | |||||
| |||||
|
|
Tuesday, November 18, 2025
Fwd: DeMets Lecture - request for information
Approaches to Address Brain Disorders
ABSTRACT:
This talk surveys a spectrum of AI approaches for biomedicine—from
classical methods to current deep-learning techniques and emerging
extensions involving agents and quantum computing. It focuses on
modeling gene-regulatory and cell-communication networks to interpret
brain disease, describing how cell-type–specific networks can be
constructed from single-cell QTLs and co-expression data and then
embedded into deep-learning frameworks to predict disease from
genotype, prioritize pathways and genes, and model perturbations for
drug-target discovery. The talk then highlights new LLM applications,
including automatic code generation and benchmarking (Biocoder),
collaborative multi-expert clinical reasoning (MedAgents), and
end-to-end single-cell analysis workflows (CellForge). Finally, it
addresses genomic-privacy challenges—first through classical
approaches such as homomorphic encryption and hidden Markov models,
and then through a quantum-computing framework that enables
distributed genomic analysis without exposing individual-level data.
==
i0mad25
Saturday, October 11, 2025
Fwd: *cyan* Invitation to Speak at Mila Bio-AI Seminar Series
AI in Biomedicine: Applications in Characterizing Variant Effects and
Drug Binding
**Abstract**
My talk will focus on key applications of deep learning in biomedicine
and artificial intelligence. In particular, I will discuss how deep
learning can be used to understand variant impact and how it has
revolutionized drug discovery and molecular design. Variant discovery
is essential for understanding how human genetic variation contributes
to disease and influences individual responses to pharmaceuticals.
Molecular discovery, in turn, is crucial for developing drugs that
effectively bind to and modulate protein targets. I will cover the
following papers in my talk (+ some others):
The EN-TEx resource of multi-tissue personal epigenomes & variant-impact models
J Rozowsky et al. (2023). Cell 186: 1493-1511e40.
Leveraging a large language model to predict protein phase transition:
a physical, multiscale and interpretable approach
M Frank et al. (2024). Proc Natl Acad Sci U S A 121: e2320510121.
Predicting Disease-Specific Histone Modifications and Functional
Effects of Non-coding Variants by Leveraging DNA Language Models
X Wang et al. (https://doi.org/10.1101/2025.06.15.659749)
Tuesday, October 7, 2025
Fwd: *cyan* Invitation to Speak at Mila Bio-AI Seminar Series
**Talk Title**
AI in Biomedicine: Applications in Characterizing Variant Effects and
Drug Binding
**Abstract**
I will provide a more detailed abstract shortly, but for now, I plan
to cover material related to the following papers (+ some others):
The EN-TEx resource of multi-tissue personal epigenomes &
variant-impact models**
J Rozowsky et al. (2023). Cell 186: 1493-1511e40.
Leveraging a large language model to predict protein phase transition:
a physical, multiscale and interpretable approach**
M Frank et al. (2024). Proc Natl Acad Sci U S A 121: e2320510121.
Predicting Disease-Specific Histone Modifications and Functional
Effects of Non-coding Variants by Leveraging DNA Language Models**
X Wang et al.
(https://doi.org/10.1101/2025.06.15.659749)
Friday, July 25, 2025
Fwd: visiting Cambridge/London in July
My talk will concern the use of endophenotypes to make more useful and
precise genetic associations. First, I will look at using large-scale
brain single-cell data to better connect genotype to neuropsychiatric
phenotypes and then to use these connections in a deep learning model
to simulate perturbations related to brain disease. Next, I will
examine an endophenotype derived from wearable biosensors, such as
smartwatches, and demonstrate that this digital phenotype can uncover
more genetic associations for brain disease than traditional clinical
associations.
==
eur25+ebi
Monday, June 9, 2025
Re: invite to give a talk at AI for health webinar on zoom
Thanks Mark. Looking forward to hosting your webinar next Wed.JimengOn Mon, Jun 2, 2025 at 2:11 PM Della L <dellaphinisee@gmail.com> wrote:Thank you Dr. Gerstein,I updated the webinar invite.Della PhiniseeVAOn Sun, Jun 1, 2025 at 9:21 PM Mark Gerstein <mark@gersteinlab.org> wrote:Title:
AI Methods for Biomedicine
ABSTRACT
My talk will focus on the following papers:
1* Current methods based on regulatory networks & deep learning
https://papers.gersteinlab.org/papers/cornerstone
https://papers.gersteinlab.org/papers/chronODE
2 * Current methods based on agents
https://papers.gersteinlab.org/papers/BioCoder
https://papers.gersteinlab.org/papers/MedAgents
https://papers.gersteinlab.org/papers/MolLM
3 * Future methods based on quantum computing
https://papers.gersteinlab.org/papers/QVAE
==
i0ai4h
Tuesday, June 3, 2025
Fwd: U1331 Computational Oncology Hybrid Seminar: Pr. Mark GERSTEIN - July 21th 2025
Computational Oncology (U1331)
________________________________
Mark GERSTEIN, Institute for Foundations of Data Science / Center for
Research Computing - Yale University (USA)
________________________________
Monday, July 21th 2025
11:00 am
Centre de Recherche - Paris Amphithéâtre Hélène Martel Massignac – 11
rue Pierre et Marie Curie, Paris 5e
+ Teams (see bottom of invitation
AI approaches for biomedicine: Cancer & Brain disorders
In this talk, I'll go over these two papers. My talk will focus on the
material in:
(1) Emani et al. (2024).
Single-cell genomics is a powerful tool for studying heterogeneous
tissues such as the brain. Yet little is understood about how genetic
variants influence cell-level gene expression. Addressing this, we
uniformly processed single-nuclei, multiomics datasets into a resource
comprising >2.8 millions nuclei from the prefrontal cortex across 388
individuals with various brain-related disorders and controls. Using
this, we built cell–type–specific gene regulatory and cell-to-cell
communication networks and an integrative deep-learning model that
accurately imputes single-cell expression and simulates perturbations.
The model prioritized ~250 disease-risk genes and drug targets with
associated cell types.
(2) Kumar et al. (2020).
I will also focus on the role of non-coding mutations in cancer.
As most know, the overwhelming part of the genome is noncoding, and
there are many somatic mutations in cancer in this region. It is still
debated the degree to which many of these mutations are under positive
selection and whether these mutations could represent either strong or
weak drivers and affect cancer progression
References
Single-cell genomics and regulatory networks for 388 human brains PS
Emani et al. (2024). Science 384: eadi5199.
Passenger Mutations in More Than 2,500 Cancer Genomes: Overall
Molecular Functional Impact and Consequences. S Kumar et al. (2020).
Cell 180: 915
Invited by:
Emmanuel BARILLOT
==
eur25
________________________________________________________________________________
Re: invite to give a talk at AI for health webinar on zoom
Thank you Dr. Gerstein,I updated the webinar invite.Della PhiniseeVAOn Sun, Jun 1, 2025 at 9:21 PM Mark Gerstein <mark@gersteinlab.org> wrote:Title:
AI Methods for Biomedicine
ABSTRACT
My talk will focus on the following papers:
1* Current methods based on regulatory networks & deep learning
https://papers.gersteinlab.org/papers/cornerstone
https://papers.gersteinlab.org/papers/chronODE
2 * Current methods based on agents
https://papers.gersteinlab.org/papers/BioCoder
https://papers.gersteinlab.org/papers/MedAgents
https://papers.gersteinlab.org/papers/MolLM
3 * Future methods based on quantum computing
https://papers.gersteinlab.org/papers/QVAE
==
i0ai4h
Monday, June 2, 2025
Re: invite to give a talk at AI for health webinar on zoom
Title:
AI Methods for Biomedicine
ABSTRACT
My talk will focus on the following papers:
1* Current methods based on regulatory networks & deep learning
https://papers.gersteinlab.org/papers/cornerstone
https://papers.gersteinlab.org/papers/chronODE
2 * Current methods based on agents
https://papers.gersteinlab.org/papers/BioCoder
https://papers.gersteinlab.org/papers/MedAgents
https://papers.gersteinlab.org/papers/MolLM
3 * Future methods based on quantum computing
https://papers.gersteinlab.org/papers/QVAE
==
i0ai4h
Sunday, June 1, 2025
Re: invite to give a talk at AI for health webinar on zoom
AI Methods for Biomedicine
ABSTRACT
My talk will focus on the following papers:
1* Current methods based on regulatory networks & deep learning
https://papers.gersteinlab.org/papers/cornerstone
https://papers.gersteinlab.org/papers/chronODE
2 * Current methods based on agents
https://papers.gersteinlab.org/papers/BioCoder
https://papers.gersteinlab.org/papers/MedAgents
https://papers.gersteinlab.org/papers/MolLM
3 * Future methods based on quantum computing
https://papers.gersteinlab.org/papers/QVAE
==
i0ai4h
Wednesday, April 9, 2025
Re: potential seminar in Center for Neural Circuit Mapping
AI Approaches for Understanding Brain Disorders
ABSTRACT
My talk will focus on the material in:
Single-cell genomics and regulatory networks for 388 human brains
Emani et al. (2024). Science.
Specifically, I'll discuss:
Single-cell genomics is a powerful tool for studying heterogeneous
tissues such as the brain. Yet little is understood about how genetic
variants influence cell-level gene expression. Addressing this, we
uniformly processed single-nuclei, multiomics datasets into a resource
comprising >2.8 million nuclei from the prefrontal cortex across 388
individuals with various brain-related disorders and controls. Using
this, we built cell–type–specific gene regulatory and cell-to-cell
communication networks and an integrative deep-learning model that
accurately imputes single-cell expression and simulates perturbations.
The model prioritized ~250
disease-risk genes and drug targets with associated cell types.
If there's time, I'll also touch on the material in :
* A Variational Graph Partitioning Approach to Modeling Protein
Liquid-liquid Phase Separation
G Wang et al. (2024). Cell Reports Physical Science.
* Leveraging a large language model to predict protein phase
transition: a physical, multiscale and interpretable approach
M Frank et al. (2024). PNAS
* Digital phenotyping from wearables using AI characterizes
psychiatric disorders and identifies genetic associations
J Liu et al. (2024). Cell.
==
i0ucla24+uci
Sunday, December 22, 2024
Re: [EXTERNAL] Re: Invitation to Science Forum Microsoft Research AI for Science
AI Approaches for Understanding Brain Disorders:
Schizophrenia, Alzheimer's disease & ADHD
Abstract:
My talk will focus on the material in:
Emani et al. (2024). Science.
Single-cell genomics and regulatory networks for 388 human brains
Specifically, I'll discuss:
Single-cell genomics is a powerful tool for studying heterogeneous
tissues such as the brain. Yet little is understood about how genetic
variants influence cell-level gene expression. Addressing this, we
uniformly processed single-nuclei, multiomics datasets into a resource
comprising >2.8 million nuclei from the prefrontal cortex across 388
individuals with various brain-related disorders and controls. For 28
harmonized neuronal and non-neuronal cell types, we assessed
population-level variation in expression and chromatin across gene
families and drug targets. Integration of expression and genotype data
revealed >1.4 million single-cell expression quantitative trait loci
(eQTLs), many of which were not seen in bulk gene-expression datasets.
The chromatin datasets allowed for the identification of >550,000
single-cell cis-regulatory elements enriched at loci linked to
brain-related traits. Combining expression, chromatin, and eQTL
datasets, we built cell type–specific gene regulatory and cell-to-cell
communication networks, which manifest cellular changes in aging and
neuropsychiatric disorders, including altered Wnt signaling in
schizophrenia and bipolar disorder. We further constructed an
integrative deep-learning model that accurately imputes single-cell
expression and simulates perturbations. The model prioritized ~250
disease-risk genes and drug targets with associated cell types,
suggesting potential precision-medicine approaches for
neuropsychiatric disorders.
If there's time, I'll also touch on the material in :
* A Variational Graph Partitioning Approach to Modeling Protein
Liquid-liquid Phase Separation
Gaoyuan Wang, Jonathan H Warrell, Suchen Zheng, Mark Gerstein (2023).
Cell Reports Physical Science.
* Leveraging a large language model to predict protein phase
transition: a physical, multiscale and interpretable approach
M Frank, P Ni, M Jensen, MB Gerstein (2024). Proc Natl Acad Sci U S A
121: e2320510121.
* Digital phenotyping from wearables using AI characterizes
psychiatric disorders and identifies genetic associations
JJ Liu, B Borsari, Y Li, SX Liu, Y Gao, X Xin, S Lou, M Jensen, D
Garrido-Martin, TL Verplaetse, G Ash, J Zhang, MJ Girgenti, W Roberts,
M Gerstein (2024). Cell.
i0msft
Tuesday, November 26, 2024
Re: [EXTERNAL] Re: Invitation to speak at the MD Anderson Virtual Data Science Forum
Hi Mark,
Fine. We'll add that in the morning to the already-posted calendar version (which included the title) and to the ListServ.
Again, best wishes. Bissan will be introducing you, so she can ask for any additional info if needed.
Best,
John and Bissan
From: Mark Gerstein <mark@gersteinlab.org>
Date: Tuesday, November 26, 2024 at 9:06 PM
To: Al-Lazikani,Bissan <BOverington@mdanderson.org>
Cc: Weinstein,John N <jweinste@mdanderson.org>, Chavez,Sergio <SChavez1@mdanderson.org>, glabstracts.mbglab@blogger.com <glabstracts.mbglab@blogger.com>
Subject: Re: [EXTERNAL] Re: Invitation to speak at the MD Anderson Virtual Data Science Forum
SLOW DOWN! - EXTERNAL SENDER: mark@gersteinlab.org Be suspicious of tone, urgency, and formatting. Do not click/open links or attachments on a mobile device. Wait until you are at a computer to confirm you are absolutely certain it is a trusted source. If you are at all uncertain use the Report Phish button and our Cybersecurity team will investigate.
TITLE:
Topics in Cancer Genomics
ABSTRACT:
My talk will cover material from the following papers:
Using sigLASSO to optimize cancer mutation signatures jointly with
sampling likelihood.
S Li, FW Crawford, MB Gerstein (2020). Nat Commun 11: 3575.
Latent Evolutionary Signatures: A General Framework for Analyzing
Music and Cultural Evolution
J Warrell, L Salichos, M Gancz, MB Gerstein (2024). J R Soc Interface
21: 20230647.
Assessing and mitigating privacy risks of sparse, noisy genotypes by
local alignment to haplotype databases.
PS Emani, MN Geradi, G Gursoy, MR Grasty, A Miranker, MB Gerstein
(2023). Genome Res 33: 2156-2173.
Unified views on variant impact across many diseases
S Kumar, M Gerstein (2023). Trends Genet 39: 442-450.
Passenger Mutations in More Than 2,500 Cancer Genomes: Overall
Molecular Functional Impact and Consequences.
S Kumar, J Warrell, S Li, PD McGillivray, W Meyerson, L Salichos, A
Harmanci, A Martinez-Fundichely, CWY Chan, MM Nielsen, L Lochovsky, Y
Zhang, X Li, S Lou, JS Pedersen, C Herrmann, G Getz, E Khurana, MB
Gerstein (2020). Cell 180: 915-927e16.
Origins and characterization of variants shared between databases of
somatic and germline human mutations.
W Meyerson, J Leisman, FCP Navarro, M Gerstein (2020). BMC
Bioinformatics 21: 227.
i0md24
Re: [EXTERNAL] Re: Invitation to speak at the MD Anderson Virtual Data Science Forum
Topics in Cancer Genomics
ABSTRACT:
My talk will cover material from the following papers:
Using sigLASSO to optimize cancer mutation signatures jointly with
sampling likelihood.
S Li, FW Crawford, MB Gerstein (2020). Nat Commun 11: 3575.
Latent Evolutionary Signatures: A General Framework for Analyzing
Music and Cultural Evolution
J Warrell, L Salichos, M Gancz, MB Gerstein (2024). J R Soc Interface
21: 20230647.
Assessing and mitigating privacy risks of sparse, noisy genotypes by
local alignment to haplotype databases.
PS Emani, MN Geradi, G Gursoy, MR Grasty, A Miranker, MB Gerstein
(2023). Genome Res 33: 2156-2173.
Unified views on variant impact across many diseases
S Kumar, M Gerstein (2023). Trends Genet 39: 442-450.
Passenger Mutations in More Than 2,500 Cancer Genomes: Overall
Molecular Functional Impact and Consequences.
S Kumar, J Warrell, S Li, PD McGillivray, W Meyerson, L Salichos, A
Harmanci, A Martinez-Fundichely, CWY Chan, MM Nielsen, L Lochovsky, Y
Zhang, X Li, S Lou, JS Pedersen, C Herrmann, G Getz, E Khurana, MB
Gerstein (2020). Cell 180: 915-927e16.
Origins and characterization of variants shared between databases of
somatic and germline human mutations.
W Meyerson, J Leisman, FCP Navarro, M Gerstein (2020). BMC
Bioinformatics 21: 227.
i0md24